EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis

David T Rubin, Joana Torres iD, Miguel Regueiro iD, Walter Reinisch iD, Lani Prideaux, Paulo G Kotze, Fiona H Tan iD, Sean Gardiner iD, Rajiv Mundayat, Mary Jane Cadatal, Siew C Ng

Crohn's & Colitis 360 · 01.01.2024 · 6 (1)

DOI: 10.1093/crocol/otae004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 20.01.2024. Verfasst von David T Rubin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). This analysis assessed the impact of cigarette smoking on tofacitinib efficacy and safety in the UC clinical program.

Methods

Efficacy endpoints and adverse events (AEs) were evaluated by smoking status (ever smokers [current and ex-smokers] and never smokers) in the phase (P)2 induction study (baseline demographics and safety only), P3 studies (OCTAVE Induction 1&2, OCTAVE Sustain, OCTAVE Open), and P3/4b RIVETING study.

Results

This post hoc analysis included 1156 patients (ever smokers, n = 416 [36.0%; current smokers, n = 59 (5.1%); ex-smokers, n = 357 (30.9%)]; never smokers, n = 740 [64.0%]; median [range] treatment duration 654 [1–2712] and 615.5 [1–2850] days, respectively). Similar proportions of ever smokers and never smokers achieved efficacy endpoints. AEs were reported in 88.7% of ever smokers and 83.8% of never smokers. Overall, 60.6% of ever smokers had an infection (serious infections, 5.5%; herpes zoster [nonserious and serious], 10.8%; Clostridioides difficile infection, 12.0%; lower respiratory tract infection, 19.5%: corresponding values among never smokers were 53.1%, 3.9%, 6.8%, 8.5%, and 11.4%). Major adverse cardiovascular events were reported in 1.0% of ever smokers and 0.7% of never smokers and thromboembolism events (venous and arterial) in 1.0% of ever smokers and 0.9% never smokers. Deaths, malignancies (excluding non-melanoma skin cancer [NMSC]), and NMSC occurred infrequently in ever smokers (0.5%, 2.5%, and 3.7%, respectively) and never smokers (0.1%, 1.5%, and 1.0%, respectively). Colorectal cancer was reported in 0.6% of never smokers; no cases occurred in ever smokers.

Conclusions

Efficacy and safety of tofacitinib were generally similar in ever smokers and never smokers. Overall, serious AEs and, as expected, infections were more frequent in ever smokers versus never smokers. This may inform treatment selection and monitoring strategies. ClinicalTrials.gov NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorcigaretteinflammatory bowel diseaseulcerative colitis

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
  • Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
  • Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal.
  • Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Joana Torres, Miguel Regueiro, Walter Reinisch, Fiona H Tan, Sean Gardiner

Förderung

  • Pfizer

Zitieren

APA

Rubin, D. T., Torres, J., Regueiro, M., Reinisch, W., Prideaux, L., Kotze, P. G., Tan, F. H., Gardiner, S., Mundayat, R., Cadatal, M. J., & Ng, S. C. (2024). Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis. Crohn's & Colitis 360, 6(1). https://doi.org/10.1093/crocol/otae004

Vancouver

Rubin DT, Torres J, Regueiro M, Reinisch W, Prideaux L, Kotze PG, et al. Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis. Crohn's & Colitis 360. 2024;6(1). doi:10.1093/crocol/otae004

BibTeX
@article{Rubin2024,
  author = {Rubin, David T and Torres, Joana and Regueiro, Miguel and Reinisch, Walter and Prideaux, Lani and Kotze, Paulo G and Tan, Fiona H and Gardiner, Sean and Mundayat, Rajiv and Cadatal, Mary Jane and Ng, Siew C},
  title = {Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis},
  journal = {Crohn's & Colitis 360},
  year = {2024},
  volume = {6},
  number = {1},
  doi = {10.1093/crocol/otae004}
}
Kostenlos starten →